ID

28085

Description

Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00806767

Lien

https://clinicaltrials.gov/show/NCT00806767

Mots-clés

Versions (1)
  1. 16/12/2017 16/12/2017 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

16 décembre 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Chronic Myeloproliferative Disorders NCT00806767

Anglais

Eligibility Chronic Myeloproliferative Disorders NCT00806767

1 Formulaires  
Criteria
Description

Criteria

diagnosis of a hematological malignancy
Description

Hematologic Neoplasm

Type de données

boolean

Alias
UMLS CUI [1]
C0376545
candidate for an allogeneic hematopoietic stem cell transplantation
Description

Allogeneic Hematopoietic Stem Cell Transplantation Scheduled

Type de données

boolean

Alias
UMLS CUI [1,1]
C1705576
UMLS CUI [1,2]
C0205539
available hla-identical related donor
Description

Donor Relative HLA Antigens Match Available

Type de données

boolean

Alias
UMLS CUI [1,1]
C0040288
UMLS CUI [1,2]
C0080103
UMLS CUI [1,3]
C0019721
UMLS CUI [1,4]
C1708943
UMLS CUI [1,5]
C0470187
patient characteristics:
Description

Client Characteristics

Type de données

boolean

Alias
UMLS CUI [1]
C0815172
who performance status (ps) 0-1 or karnofsky ps 70-100%
Description

WHO performance status scale | Karnofsky Performance Status

Type de données

boolean

Alias
UMLS CUI [1]
C1298650
UMLS CUI [2]
C0206065
life expectancy > 6 months
Description

Life Expectancy

Type de données

boolean

Alias
UMLS CUI [1]
C0023671
lvef ≥ 40%
Description

Left ventricular ejection fraction

Type de données

boolean

Alias
UMLS CUI [1]
C0428772
dlco ≥ 50%
Description

Carbon Monoxide Diffusing Capability Test

Type de données

boolean

Alias
UMLS CUI [1]
C1516251
creatinine clearance ≥ 30 ml/min
Description

Creatinine clearance measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0373595
transaminases and/or bilirubin ≤ 2 times upper limit of normal (uln)
Description

Transaminases | Serum total bilirubin measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0002594
UMLS CUI [2]
C1278039
no other cancer within the past 5 years, except for basal cell carcinoma of the skin or carcinoma in situ of the cervix
Description

Exclusion Cancer Other | Exception Basal cell carcinoma | Exception Carcinoma in situ of uterine cervix

Type de données

boolean

Alias
UMLS CUI [1,1]
C2828389
UMLS CUI [1,2]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0007117
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0851140
no human t-cell leukemia virus type 1 positivity
Description

Exclusion | Human t-cell leukemia virus 1 Positive

Type de données

boolean

Alias
UMLS CUI [1,1]
C2828389
UMLS CUI [1,2]
C0020094
UMLS CUI [1,3]
C1514241
no hiv positivity
Description

Exclusion HIV Seropositivity

Type de données

boolean

Alias
UMLS CUI [1,1]
C2828389
UMLS CUI [1,2]
C0019699
no uncontrolled bacterial, viral, or fungal infection
Description

Exclusion Criteria | Bacterial Infection Uncontrolled | Virus Disease Uncontrolled | Mycoses Uncontrolled

Type de données

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2,1]
C0004623
UMLS CUI [2,2]
C0205318
UMLS CUI [3,1]
C0042769
UMLS CUI [3,2]
C0205318
UMLS CUI [4,1]
C0026946
UMLS CUI [4,2]
C0205318
no contraindications to the study drugs
Description

Exclusion | Medical contraindication Investigational New Drugs

Type de données

boolean

Alias
UMLS CUI [1]
C2828389
UMLS CUI [2,1]
C1301624
UMLS CUI [2,2]
C0013230
no concurrent serious and uncontrolled disease
Description

Exclusion | Comorbidity Serious Uncontrolled

Type de données

boolean

Alias
UMLS CUI [1]
C2828389
UMLS CUI [2,1]
C0009488
UMLS CUI [2,2]
C0205404
UMLS CUI [2,3]
C0205318
prior concurrent therapy:
Description

Therapeutic procedure

Type de données

boolean

Alias
UMLS CUI [1]
C0087111
at least 1 month since prior participation in a clinical trial
Description

Study Subject Participation Status

Type de données

boolean

Alias
UMLS CUI [1]
C2348568
Retour au début de la page

Similar models

Eligibility Chronic Myeloproliferative Disorders NCT00806767

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Hematologic Neoplasm
Item
diagnosis of a hematological malignancy
boolean
C0376545 (UMLS CUI [1])
Allogeneic Hematopoietic Stem Cell Transplantation Scheduled
Item
candidate for an allogeneic hematopoietic stem cell transplantation
boolean
C1705576 (UMLS CUI [1,1])
C0205539 (UMLS CUI [1,2])
Donor Relative HLA Antigens Match Available
Item
available hla-identical related donor
boolean
C0040288 (UMLS CUI [1,1])
C0080103 (UMLS CUI [1,2])
C0019721 (UMLS CUI [1,3])
C1708943 (UMLS CUI [1,4])
C0470187 (UMLS CUI [1,5])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
WHO performance status scale | Karnofsky Performance Status
Item
who performance status (ps) 0-1 or karnofsky ps 70-100%
boolean
C1298650 (UMLS CUI [1])
C0206065 (UMLS CUI [2])
Life Expectancy
Item
life expectancy > 6 months
boolean
C0023671 (UMLS CUI [1])
Left ventricular ejection fraction
Item
lvef ≥ 40%
boolean
C0428772 (UMLS CUI [1])
Carbon Monoxide Diffusing Capability Test
Item
dlco ≥ 50%
boolean
C1516251 (UMLS CUI [1])
Creatinine clearance measurement
Item
creatinine clearance ≥ 30 ml/min
boolean
C0373595 (UMLS CUI [1])
Transaminases | Serum total bilirubin measurement
Item
transaminases and/or bilirubin ≤ 2 times upper limit of normal (uln)
boolean
C0002594 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
Exclusion Cancer Other | Exception Basal cell carcinoma | Exception Carcinoma in situ of uterine cervix
Item
no other cancer within the past 5 years, except for basal cell carcinoma of the skin or carcinoma in situ of the cervix
boolean
C2828389 (UMLS CUI [1,1])
C1707251 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0851140 (UMLS CUI [3,2])
Exclusion | Human t-cell leukemia virus 1 Positive
Item
no human t-cell leukemia virus type 1 positivity
boolean
C2828389 (UMLS CUI [1,1])
C0020094 (UMLS CUI [1,2])
C1514241 (UMLS CUI [1,3])
Exclusion HIV Seropositivity
Item
no hiv positivity
boolean
C2828389 (UMLS CUI [1,1])
C0019699 (UMLS CUI [1,2])
Exclusion Criteria | Bacterial Infection Uncontrolled | Virus Disease Uncontrolled | Mycoses Uncontrolled
Item
no uncontrolled bacterial, viral, or fungal infection
boolean
C0680251 (UMLS CUI [1])
C0004623 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0042769 (UMLS CUI [3,1])
C0205318 (UMLS CUI [3,2])
C0026946 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
Exclusion | Medical contraindication Investigational New Drugs
Item
no contraindications to the study drugs
boolean
C2828389 (UMLS CUI [1])
C1301624 (UMLS CUI [2,1])
C0013230 (UMLS CUI [2,2])
Exclusion | Comorbidity Serious Uncontrolled
Item
no concurrent serious and uncontrolled disease
boolean
C2828389 (UMLS CUI [1])
C0009488 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C0205318 (UMLS CUI [2,3])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
Study Subject Participation Status
Item
at least 1 month since prior participation in a clinical trial
boolean
C2348568 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial